Q3 2024 EPS Estimates for Johnson & Johnson (NYSE:JNJ) Decreased by Analyst

Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Zacks Research dropped their Q3 2024 earnings per share (EPS) estimates for shares of Johnson & Johnson in a research report issued on Thursday, September 26th. Zacks Research analyst K. Shah now expects that the company will earn $2.12 per share for the quarter, down from their prior estimate of $2.22. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.02 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q4 2024 earnings at $2.33 EPS, FY2024 earnings at $9.98 EPS, Q3 2025 earnings at $2.59 EPS, Q4 2025 earnings at $2.63 EPS, FY2025 earnings at $10.58 EPS, Q1 2026 earnings at $2.76 EPS, Q2 2026 earnings at $2.82 EPS and FY2026 earnings at $11.27 EPS.

Several other equities analysts have also issued reports on the stock. Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $162.02 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market capitalization of $389.93 billion, a PE ratio of 10.10, a P/E/G ratio of 2.69 and a beta of 0.53. The company has a 50-day simple moving average of $162.50 and a two-hundred day simple moving average of $154.21. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the firm earned $2.80 earnings per share.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently modified their holdings of the stock. Innealta Capital LLC acquired a new stake in Johnson & Johnson during the second quarter worth about $27,000. MFA Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $43,000. Vermillion & White Wealth Management Group LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at about $44,000. Fairfield Financial Advisors LTD acquired a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $46,000. Finally, Grayhawk Investment Strategies Inc. grew its position in shares of Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after buying an additional 259 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.